Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients

Rigolin et al. used genomic microarrays (GM) to refine prognosis of patients with newly diagnosed low-risk CLL. The authors found a significant correlation between the presence of additional lesions by GM and adverse prognostic features including advanced stage, high risk, and presence of a complex karyotype. No similar associations were found when using NGS to assess the presence of genetic mutations across 20 commonly associated genes. Findings suggest that GM may have a place in improving overall patient care, especially for those patients who may benefit from a risk-adapted follow-up due to prediction of worse outcomes.